MedTrace Logo

Outcome of Patients With Primary Aldosteronism

NCT04428827 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2021-08-12

No results posted yet for this study

Summary

Majority of patients with hypertension have primary hypertension (without an underlying cause). Primary aldosteronism (PA) is the most common cause of secondary hypertension, and can be found in 5-10% of patients locally. PA is caused by excessive release of a hormone (aldosterone) from the adrenal glands, which can be unilateral (one gland) or bilateral (both glands).

It has been shown that excess aldosterone has other harmful effects in addition to hypertension, such as directly affecting the heart, blood vessels, kidneys, leading to increased cardiovascular morbidity and mortality. This is supported by studies showing reversal of these effects after treatment for PA.

The investigators aim to assess the long-term cardiovascular, and renal outcomes of patients with PA, compared to patients with essential hypertension.

Conditions

  • Primary Aldosteronism
  • Primary Aldosteronism Due to Aldosterone Producing Adenoma
  • Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
  • Adrenalectomy; Status
  • Mineralocorticoid Excess
  • Mineralocorticoid Antagonists [Aldosterone Antagonists] Causing Adverse Effects in Therapeutic Use
  • Cardiovascular Morbidity
  • Chronic Renal Disease
  • Hypokalemia

Interventions

PROCEDURE

Unilateral adrenalectomy in patients with unilateral disease

Unilateral adrenalectomy in patients with unilateral disease

Sponsors & Collaborators

  • Singapore General Hospital

    collaborator OTHER

  • Changi General Hospital

    lead OTHER

Principal Investigators

  • Troy Puar, MRCP · Changi General Hospital

Eligibility

Min Age
14 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2022-07-30
Completion
2022-07-30

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04428827 on ClinicalTrials.gov